Prime Medicine, Inc. (PRME) stock
PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.82−0.02 (-0.52%)
Close on Nov 18, 2026Market cap $692.86MP/E –Yield –
Prime Medicine operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Prime Medicine's operating income for the twelve months ending Jun 30, 2026 was -$196.52M. For fiscal 2025 it was -$208.35M. The highest annual figure on record is -$932.00K in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$208.35M | – |
| FY2024 | Dec 31, 2024 | -$202.47M | – |
| FY2023 | Dec 31, 2023 | -$204.79M | – |
| FY2022 | Dec 31, 2022 | -$116.54M | – |
| FY2021 | Dec 31, 2021 | -$84.47M | – |
| FY2020 | Dec 31, 2020 | -$932.00K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$43.29M | – |
| Q1 FY2026 | Mar 31, 2026 | -$50.65M | – |
| Q4 FY2025 | Dec 31, 2025 | -$48.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$53.97M | – |
| Q2 FY2025 | Jun 30, 2025 | -$53.38M | – |
| Q1 FY2025 | Mar 31, 2025 | -$52.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$44.22M | – |
| Q3 FY2024 | Sep 30, 2024 | -$54.23M | – |
| Q2 FY2024 | Jun 30, 2024 | -$55.67M | – |
| Q1 FY2024 | Mar 31, 2024 | -$48.34M | – |
| Q4 FY2023 | Dec 31, 2023 | -$68.04M | – |
| Q3 FY2023 | Sep 30, 2023 | -$51.46M | – |
| Q2 FY2023 | Jun 30, 2023 | -$45.26M | – |
| Q1 FY2023 | Mar 31, 2023 | -$40.03M | – |
| Q4 FY2022 | Dec 31, 2022 | -$38.69M | – |
| Q3 FY2022 | Sep 30, 2022 | -$31.66M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.31M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.90M | – |
| Q4 FY2021 | Dec 31, 2021 | -$60.08M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.43M | – |
See a number that looks wrong?